Department of Endocrinology, St Vincent's Hospital, Diabetes and Obesity Program, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Curr HIV/AIDS Rep. 2012 Sep;9(3):206-17. doi: 10.1007/s11904-012-0124-x.
Treatment of HIV infection with highly active antiretroviral therapy (HAART) confers survival and quality of life benefits. However, these significant benefits are at the cost of metabolic complications with associated increased risk of type 2 diabetes and cardiovascular disease. These chronic diseases add complexity to the standards of care in HIV infection and much remains unknown about the natural histories of diabetes and hyperlipidemia in this setting. This review examines recent research findings in diabetes and hyperlipidemia in HIV infection, juxtaposed on our prior understanding of these diseases. It also reviews the current evidence base and clinical guidelines for diabetes and lipid management and cardiometabolic prevention in HIV-infected HAART recipients.
高效抗逆转录病毒疗法 (HAART) 治疗 HIV 感染可带来生存和生活质量获益。然而，这些显著获益是以代谢并发症为代价的，相关风险增加了 2 型糖尿病和心血管疾病的风险。这些慢性疾病给 HIV 感染的护理标准增加了复杂性，并且对于该环境下糖尿病和血脂异常的自然史仍知之甚少。本综述在我们既往对这些疾病的理解基础上，检查了 HIV 感染中糖尿病和血脂异常的最新研究结果。它还回顾了 HIV 感染的 HAART 受者中糖尿病和血脂管理以及心脏代谢预防的当前证据基础和临床指南。
Zotero 插件